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More than 40 years after the first publication, analgesic
nephropathy still remains a controversial issue. During
the 60s and 70s, phenacetin was singled out as the
nephrotoxic culprit. Some countries reacted early by
banning all phenacetin-containing products from the
'over-the-counter' market (Sweden, 1961; Canada,
1973). In other countries phenacetin was removed
from analgesic mixtures by the pharmaceutical industry
long before legislative measures were taken
(Switzerland, Germany, Belgium). By 1996, phenacetin
use had ceased for more than 10 years in Western
Europe. Analgesic nephropathy however, remains a
common disease in several areas. Although a decrease
in the national incidence has been observed in several
West European countries, in Eastern Europe analgesic
nephropathy has gained recognition. Unexpectedly
high incidences were recently measured in e.g. Czech
and Slovak Republics [1].
During the last decade, scientists demonstrated the
renal risk of other analgesic mixtures not containing
phenacetin and many clinicians diagnosed analgesic
nephropathy in patients who never consumed phen-
acetin. The recent publications investigating the
nephrotoxic potential of paracetamol [2], the recom-
mendations of the National Kidney Foundation of the
United States [3] and the recent legislative actions in
Belgium focused on all analgesic mixtures revived the
discussion concerning the nephrotoxicity of the many
analgesic combinations currently available.
The fact that analgesic nephropathy is one of the
few preventable renal diseases, makes worthy the
investment to establish clear statements regarding this
issue. The statements presented here deal with and are
limited to 'classic' analgesic nephropathy. This particu-
lar form of renal disease is characterized by renal
papillary necrosis and chronic interstitial nephritis
associated with prolonged and excessive consumption
of analgesic mixtures containing addictive substances.
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NSAID-related renal toxicity, mainly presented as
acute renal failure and serious fluid and electrolyte
disorders, is excluded from the discussion.
The following statements represent our opinion con-
cerning the current status of analgesic nephropathy:
1. Attempts to evaluate the nephrotoxicity of different
analgesics using experimental animal models have
yielded conflicting results. Experimental analgesic
nephropathy and renal papillary necrosis can be
induced in animals with different kinds of analgesics.
Moreover, the experimental data provide a biochem-
ical and pathological basis for the enhanced renal
toxicity of analgesic mixtures compared with that
of single agents. The use of extremely high doses
and the aggravation of the renal effects by dehydra-
tion or by introducing bacteria, however makes the
extrapolation from the experimental data to anal-
gesic nephropathy observed in humans difficult [4].
2. In humans, there is overwhelming clinical evidence
linking analgesic abuse with a particular form of
chronic renal damage evolving towards end-stage
renal failure. The association between analgesic
consumption and the development of renal impair-
ment was further investigated in the case-control
studies published during the last decade [2,5,6,7].
The strongest proof of causality came from the two
prospective studies published following the renal
function of healthy abusers and controls during a
period of several years [8,9].
3. The long-standing excessive use of analgesics
observed in patients with analgesic nephropathy is
concentrated on combination analgesics. Abusers
prefer analgesic mixtures rather than single anal-
gesics, taking these products rather for their mood-
altering effects than for the relief of physical com-
plaints. Hence, all these mixtures contain caffeine
and/or codeine and it is clearly established that the
addition of these substances can create a psycholo-
gical dependence towards these drugs [10].
4. Analgesic nephropathy is caused by the abuse of
analgesic mixtures containing two analgesic compon-
ents combined with potentially addictive substances
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(2+ analgesics). Evidence came in the first place
from the clinicians confronted with the history of
abuse obtained from their patients with analgesic
nephropathy. Further evidence came from the case
control study of Pommer et al. showing an increased
odds ratio for all combined analgesics but not for
the single ones [6]. Moreover, Elseviers and De
Broe reported that in 219 out of 226 patients with
analgesic nephropathy diagnosed according to
objective renal imaging criteria, the abuse was con-
centrated on analgesic mixtures [11].
5. Last year the ad hoc committee of the National
Kidney Foundation in the US examined data avail-
able from the peer-review medical literature in form-
ing opinions regarding analgesic nephropathy [3].
The available information, gathered from hundreds
of peer-reviewed articles, suggests that habitual con-
sumption of both phenacetin-containing mixtures and
non-phenacetin-containing mixtures is associated with
analgesic nephropathy. Phenacetin can no longer be
considered as the only nephrotoxic culprit in analgesic
mixtures. Clinical observations in countries where
analgesics without phenacetin are on the market for
a period of more than 20 years (e.g. Australia,
Belgium, Germany) learned that identical renal
pathology is observed in patients abusing analgesic
mixtures which never contained phenacetin. The
diagnostic criteria studies documented the nephro-
toxicity of the combinations of salicylic acid-
paracetamol, salicylic acid-pyrazolones, paracet-
amol-pyrazolones, and two pyrazolones [11].
6. The problem of chronic analgesic toxicity can be
prevented efficaciously by curtailing heavy con-
sumption. That educational and voluntary restraint
alike should have but little effect on analgesic abuse
is understandable, even predictable, given the
addictive nature of analgesic mixtures. The most
rational approach to prevention of classical analgesic
nephropathy is the prohibition of 'over-the-counter'
sales of any analgesic mixture containing two anal-
gesic components combined with caffeine and/or cod-
eine. The Australian experience learned that by
limiting the 'over-the-counter' availability of anal-
gesic mixtures, the disease almost disappeared [12].
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Editor's note
Please see also the letter to the Editor by Fox (pp. 2519-2520 in
this issue).
